Navigation Links
Clinilabs Welcomes Anesthesiologist Dr. Admir Hadzic Who Will Provide CSF/cCSF Capabilities For Clinilabs
Date:4/30/2013

NEW YORK, April 30, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, today announced the arrival of Dr. Admir Hadzic to the Clinilabs team.  Dr. Hadzic will provide expertise in the development of drugs to treat pain, and also will manage the collection of CSF/cCSF samples in clinical trials.

Dr. Admir Hadzic has been at the forefront of academic anesthesiology for nearly two decades. His work has substantially contributed to the development of functional regional anesthesia anatomy, standardized techniques of nerve blocks, patient outcome benefits of regional anesthesia, and monitoring principles to standardize the practice and decrease the risk of complications of nerve blocks.  He has published numerous peer-reviewed articles and two leading textbooks, and is a founder of the global educational programs Networking World Anesthesia Convention and the New York School of Regional Anesthesia. Through these educational programs, Dr. Hadzic has trained physicians Worldwide in anesthesia techniques and other procedures such as CSF sampling. 

Dr. Gary Zammit , President and CEO of Clinilabs, states "Clinilabs is pleased to welcome Dr. Hadzic to our team.  He is a leader in the field of anesthesia who significantly broadens the capabilities we are able to offer our clients.  We look forward to his consultancy on multicenter pain trials that we manage, as well as his hands-on contribution to the trials being conducted at our NYC and NJ Phase I units that require anesthesia services." 

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations.  The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide.  Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths.  Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects.  For more information, please visit www.clinilabs.com.

Media Contact: Hannah DAoust , Clinilabs, 646-215-6480, hdaoust@clinilabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. EMBO welcomes 55 leading life scientists as members
2. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
3. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
4. The CNIO welcomes the new academic year with a spotlight on cancer genetics
5. Chiltern Welcomes Cedric Burg And James Gunter
6. Mayo Clinic anesthesiologist earns APSs Walter B. Cannon Award
7. Reproductive health providers should discuss environmental exposure risks with patients
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. Artificial wetlands can provide benefits over the long haul
10. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
11. Heightened Security Threats and Economic Issues Provide Fillip to Global Civil and Military Biometrics Market, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: